Literature DB >> 18509201

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.

Fei Liu1, Zhihou Liang, Jerzy Wegiel, Yu-Wen Hwang, Khalid Iqbal, Inge Grundke-Iqbal, Narayan Ramakrishna, Cheng-Xin Gong.   

Abstract

Adults with Down syndrome (DS) develop Alzheimer neurofibrillary degeneration in the brain, but the underlying molecular mechanism is unknown. Here, we report that the presence of an extra copy of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A (Dyrk1A) gene due to trisomy 21 resulted in overexpression of Dyrk1A and elevated kinase activity in DS brain. Dyrk1A phosphorylated tau at several sites, and these sites were hyperphosphorylated in adult DS brains. Phosphorylation of tau by Dyrk1A primed its further phosphorylation by glycogen synthase kinase-3beta (GSK-3beta). Dyrk1A-induced tau phosphorylation inhibited tau's biological activity and promoted its self-aggregation. In Ts65Dn mouse brain, an extra copy of the Dyrk1A gene caused increased expression and activity of Dyrk1A and resulted in increased tau phosphorylation. These findings strongly suggest a novel mechanism by which the overexpression of Dyrk1A in DS brain causes neurofibrillary degeneration via hyperphosphorylating tau.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509201      PMCID: PMC2518253          DOI: 10.1096/fj.07-104539

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  59 in total

1.  Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.

Authors:  C X Gong; T Lidsky; J Wegiel; L Zuck; I Grundke-Iqbal; K Iqbal
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

Review 2.  Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

Authors:  Rudolph E Tanzi; Lars Bertram
Journal:  Cell       Date:  2005-02-25       Impact factor: 41.582

3.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.

Authors:  Yousang Gwack; Sonia Sharma; Julie Nardone; Bogdan Tanasa; Alina Iuga; Sonal Srikanth; Heidi Okamura; Diana Bolton; Stefan Feske; Patrick G Hogan; Anjana Rao
Journal:  Nature       Date:  2006-03-01       Impact factor: 49.962

4.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.

Authors:  Y L Woods; P Cohen; W Becker; R Jakes; M Goedert; X Wang; C G Proud
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

5.  Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation.

Authors:  Eun Joo Kim; Jee Young Sung; Hyun Jung Lee; Hyewhon Rhim; Masato Hasegawa; Takeshi Iwatsubo; Do Sik Min; Jongsun Kim; Seung R Paik; Kwang Chul Chung
Journal:  J Biol Chem       Date:  2006-09-07       Impact factor: 5.157

6.  Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.

Authors:  Mitsuko Hashiguchi; Taro Saito; Shin-ichi Hisanaga; Toshio Hashiguchi
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

7.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

8.  Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases.

Authors:  W Becker; Y Weber; K Wetzel; K Eirmbter; F J Tejedor; H G Joost
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions.

Authors:  Theresa J Kannanayakal; Haiyang Tao; Dale D Vandre; Jeff Kuret
Journal:  Acta Neuropathol       Date:  2006-03-24       Impact factor: 17.088

10.  The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site.

Authors:  Katrin de Graaf; Hanna Czajkowska; Sabine Rottmann; Len C Packman; Richard Lilischkis; Bernhard Lüscher; Walter Becker
Journal:  BMC Biochem       Date:  2006-03-02       Impact factor: 4.059

View more
  92 in total

1.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

2.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.

Authors:  Jerzy Wegiel; Karol Dowjat; Wojciech Kaczmarski; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur Kolecka; Jarek Wegiel; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Cheng-Xin Gong; Fei Liu; Tatyana Adayev; Mo-Chou Chen-Hwang; Yu-Wen Hwang
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

3.  Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons.

Authors:  Timothy M E Scales; Shen Lin; Michaela Kraus; Robert G Goold; Phillip R Gordon-Weeks
Journal:  J Cell Sci       Date:  2009-06-23       Impact factor: 5.285

4.  Nuclear import of the DSCAM-cytoplasmic domain drives signaling capable of inhibiting synapse formation.

Authors:  Sonja M Sachse; Sam Lievens; Luís F Ribeiro; Dan Dascenco; Delphine Masschaele; Katrien Horré; Anke Misbaer; Nele Vanderroost; Anne Sophie De Smet; Evgenia Salta; Maria-Luise Erfurth; Yoshiaki Kise; Siegfried Nebel; Wouter Van Delm; Stéphane Plaisance; Jan Tavernier; Bart De Strooper; Joris De Wit; Dietmar Schmucker
Journal:  EMBO J       Date:  2019-02-11       Impact factor: 11.598

5.  Intracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A).

Authors:  Wojciech Kaczmarski; Madhabi Barua; Bozena Mazur-Kolecka; Janusz Frackowiak; Wieslaw Dowjat; Pankaj Mehta; David Bolton; Yu-Wen Hwang; Ausma Rabe; Giorgio Albertini; Jerzy Wegiel
Journal:  J Neurosci Res       Date:  2013-11-22       Impact factor: 4.164

6.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.

Authors:  Nana Jin; Xiaomin Yin; Jianlan Gu; Xinhua Zhang; Jianhua Shi; Wei Qian; Yuhua Ji; Maohong Cao; Xiaosong Gu; Fei Ding; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

7.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases.

Authors:  Yang Yu; Xiaoqin Run; Zhihou Liang; Yi Li; Fei Liu; Ying Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-01-13       Impact factor: 5.372

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

9.  DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.

Authors:  José Luis Vázquez-Higuera; Pascual Sánchez-Juan; Eloy Rodríguez-Rodríguez; Ignacio Mateo; Ana Pozueta; Ana Frank; Isabel Sastre; Fernando Valdivieso; José Berciano; María J Bullido; Onofre Combarros
Journal:  BMC Med Genet       Date:  2009-12-08       Impact factor: 2.103

10.  MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.

Authors:  Olivier C Maes; Howard M Chertkow; Eugenia Wang; Hyman M Schipper
Journal:  Curr Genomics       Date:  2009-05       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.